Related Experiment Video
Updated: Aug 12, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
Why we need new strategies in CHF management
1University of Glasgow, Glasgow, G12 8QQ, UK. j.mcmurray@bio.gla.ac.uk
Insights
Congestive heart failure (CHF) management needs improvement due to rising prevalence. Angiotensin II type 1 receptor blockers show promise, alongside enhanced patient education and monitoring by nurses for better treatment compliance.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) prevalence is increasing, driven by an aging population and improved myocardial infarction survival.
- Current drug therapies require enhancement for effective CHF management.
Purpose of the Study:
- To explore the potential of angiotensin II type 1 (AT(1))-receptor blockers in CHF management.
- To highlight the role of specialized nurses in improving patient compliance and holistic CHF care.
Main Methods:
- Review of early trials and ongoing large-scale outcome studies on AT(1)-receptor blockers for CHF.
- Emphasis on the integration of patient education and monitoring by nurses.
Main Results:
- AT(1)-receptor blockers demonstrate placebo-like tolerability and promising early trial results for CHF.
- Specially trained nurses can improve adherence to existing and novel CHF therapies.
Conclusions:
- AT(1)-receptor blockers represent a potential advancement in CHF treatment strategies.
- Enhanced patient education and monitoring by nurses are crucial for optimizing CHF management and improving patient outcomes.
Abstract:
Despite recent improvements in drug therapy, the prevalence of congestive heart failure (CHF) continues to rise, as a result of the increasing proportion of older people in the population and factors such as greater survival rates after myocardial infarction. More effective management strategies for CHF are therefore needed urgently. The angiotensin II type 1 (AT(1))-receptor blockers might contribute to such strategies, offering placebo-like tolerability and showing promise in early trials of their use in CHF. Large-scale outcome studies, currently underway, will provide further evidence of the value of AT(1)-receptor blockers in CHF. In addition, the involvement of specially trained nurses in patient education and monitoring should enhance compliance with both existing and novel therapies, and thus help to increase the overall efficacy of holistic strategies for CHF management.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions
Cardiomyopathy V: Interprofessional Care
Atherosclerosis III: Management
Chronic Kidney Disease IV: Nursing Management
